Patents by Inventor Carole Bataille

Carole Bataille has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds useful in the treatment of disorders associated with mutant RAS
    Patent number: 11970469
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 30, 2024
    Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Terrence Rabbitts, Camilo Quevedo, Carole Bataille
  • LMO2 PROTEIN INHIBITORS
    Publication number: 20230303544
    Abstract: The present invention relates to compounds of Formula (I) that function as LMO2 activity: Formula (I) wherein R1, X1, X2, X3, Q, R2, R3 and R4 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which LMO2 activity is implicated.
    Type: Application
    Filed: August 18, 2021
    Publication date: September 28, 2023
    Inventors: Terence Rabbits, Nicolas Bery, Carole Bataille, Angela Russell
  • COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS
    Publication number: 20210214322
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Application
    Filed: June 3, 2019
    Publication date: July 15, 2021
    Inventors: Terrence RABBITTS, Camilo QUEVEDO, Carole BATAILLE
  • Quinoline compounds
    Patent number: 9822078
    Abstract: The present invention relates to quinoline compounds as defined by Formula I below. Such quinoline compounds have been shown to inhibit the formation of amyloid deposits (e.g., amyloid oligomers, fibrils or plaques). Consequently, these compounds are suitable for treating a range of diseases and disorders in which amyloid deposits are implicated, such as type-2 diabetes and Alzheimer's disease.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: November 21, 2017
    Assignee: Oxford University Innovation Limited
    Inventors: David Vaux, Letitia Jean, Stephen Davies, Angela Russell, Graham Wynne, Carole Bataille, Méabh Brennan
  • QUINOLINE COMPOUNDS
    Publication number: 20170008849
    Abstract: The present invention relates to quinoline compounds as defined by Formula I below. Such quinoline compounds have been shown to inhibit the formation of amyloid deposits (e.g., amyloid oligomers, fibrils or plaques). Consequently, these compounds are suitable for treating a range of diseases and disorders in which amyloid deposits are implicated, such as type-2 diabetes and Alzheimer's disease.
    Type: Application
    Filed: February 27, 2015
    Publication date: January 12, 2017
    Inventors: David Vaux, Letitia Dean, Stephen Davies, Angela Russell, Graham Wynne, Carole Bataille, Méabh Brennan